Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan
· Delayed Price · Currency is TWD 611.00
+10.00 (1.66%)
Dec 2, 2024, 9:00 AM CST
TPE:6919 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | 44.43 | 38.93 | 12.82 | 12.34 | 10.35 | Upgrade
|
| Revenue Growth (YoY) | 14.13% | 203.68% | 3.90% | 19.22% | -44.50% | Upgrade
|
| Cost of Revenue | 13.67 | 11.46 | 3.21 | 3.11 | 3.68 | Upgrade
|
| Gross Profit | 30.76 | 27.47 | 9.61 | 9.23 | 6.68 | Upgrade
|
| Selling, General & Admin | 97.79 | 36.95 | 34.21 | 59.35 | 23.29 | Upgrade
|
| Research & Development | 650.12 | 503.99 | 295.02 | 180.62 | 88.98 | Upgrade
|
| Operating Expenses | 747.91 | 540.94 | 329.23 | 239.97 | 112.28 | Upgrade
|
| Operating Income | -717.14 | -513.47 | -319.62 | -230.73 | -105.6 | Upgrade
|
| Interest Expense | -0.33 | -0.5 | -0.67 | -2.9 | -4.51 | Upgrade
|
| Interest & Investment Income | 74.21 | 17.42 | 5.19 | 0.1 | 0.04 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -1.03 | 14.23 | -1.07 | 5.87 | Upgrade
|
| Other Non Operating Income (Expenses) | 54.44 | 9.12 | 14.83 | 10.34 | 5.81 | Upgrade
|
| EBT Excluding Unusual Items | -588.83 | -488.46 | -286.05 | -224.26 | -98.4 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | -0.11 | - | - | Upgrade
|
| Pretax Income | -588.83 | -488.46 | -286.16 | -224.26 | -98.4 | Upgrade
|
| Income Tax Expense | - | - | - | 0.03 | 0.09 | Upgrade
|
| Net Income | -588.83 | -488.46 | -286.16 | -224.29 | -98.49 | Upgrade
|
| Net Income to Common | -588.83 | -488.46 | -286.16 | -224.29 | -98.49 | Upgrade
|
| Shares Outstanding (Basic) | 143 | 124 | 117 | 92 | 74 | Upgrade
|
| Shares Outstanding (Diluted) | 143 | 124 | 117 | 92 | 74 | Upgrade
|
| Shares Change (YoY) | 15.36% | 5.77% | 27.35% | 23.49% | 6.52% | Upgrade
|
| EPS (Basic) | -4.12 | -3.94 | -2.44 | -2.44 | -1.32 | Upgrade
|
| EPS (Diluted) | -4.12 | -3.94 | -2.44 | -2.44 | -1.32 | Upgrade
|
| Free Cash Flow | -532.31 | -432.54 | -256.93 | -125.6 | -47.24 | Upgrade
|
| Free Cash Flow Per Share | -3.72 | -3.49 | -2.19 | -1.37 | -0.63 | Upgrade
|
| Gross Margin | 69.23% | 70.56% | 74.94% | 74.83% | 64.49% | Upgrade
|
| Operating Margin | -1613.95% | -1318.88% | -2493.17% | -1869.95% | -1020.30% | Upgrade
|
| Profit Margin | -1325.18% | -1254.64% | -2232.10% | -1817.76% | -951.56% | Upgrade
|
| Free Cash Flow Margin | -1197.97% | -1111.01% | -2004.12% | -1017.90% | -456.41% | Upgrade
|
| EBITDA | -687.64 | -493.68 | -302.36 | -214.49 | -94.43 | Upgrade
|
| D&A For EBITDA | 29.51 | 19.79 | 17.26 | 16.24 | 11.17 | Upgrade
|
| EBIT | -717.14 | -513.47 | -319.62 | -230.73 | -105.6 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.